Mapping the AI-Enabled Medical Device Landscape in Australia and the United States: a Comparative Analysis of FDA and TGA Listings

This cross-sectional descriptive study mapped the AI-enabled medical device landscape in Australia and the United States using the FDA AI/ML-enabled medical device list and the TGA AI-enabled medical devices list, current as of 5th January 2026. We compared medical specialty distribution, AI function, regulatory risk classification, and manufacturer origin, and characterised the overlap between the two lists. We identified 1,357 FDA listings and 125 TGA listings. Radiology dominated both markets (FDA 76.5%, TGA 60.8%), but Australia had different specialty diversity to the US, including orthopaedic (2.4%) and dental (3.2%) devices. AI image and signal interpretation was most common (FDA 57.5%, TGA 38.4%), whereas measurement, treatment planning, and workflow support were relatively more prominent in Australia. Nearly all FDA devices were Class II (98.8%), while TGA devices spanned low to high-risk classes. Top contributors to Australia’s AI market were the USA (28.8%), Australia (9.6%), and China (8.8%). Of the 125 TGA listings, 71 (56.8%) had a matching FDA listing. Among these 71 matched TGA listings, 15 were listed in Australia prior to the USA, while the remaining 56 were FDA-listed first. Australia’s AI device market is smaller, but still diverse, and includes multiple Australian-headquartered manufacturers. The substantial overlap between the two lists, predominantly with prior FDA listing, suggests the Australian market draws on internationally developed technologies, although listing dates do not establish when devices became available to clinicians. These descriptive findings provide a benchmark for future comparative and longitudinal research as both markets continue to develop.

Authors

Institutions

Publication Details

Journal
Journal of Medical Systems
Published
2026-11-19
DOI
https://doi.org/10.1007/s10916-026-02491-1
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mapping the AI-Enabled Medical Device Landscape in Australia and the United States: a Comparative Analysis of FDA and TGA Listings

Mariam Rowe, Dylan Stubbs, Dylan Rowe
3 links
Journal of Medical Systems
Healthcare Regulation
article

Mapping the AI-Enabled Medical Device Landscape in Australia and the United States: a Comparative Analysis of FDA and TGA Listings

Mariam Rowe, Dylan Stubbs, Dylan Rowe
article en

Abstract

This cross-sectional descriptive study mapped the AI-enabled medical device landscape in Australia and the United States using the FDA AI/ML-enabled medical device list and the TGA AI-enabled medical devices list, current as of 5th January 2026. We compared medical specialty distribution, AI function, regulatory risk classification, and manufacturer origin, and characterised the overlap between the two lists. We identified 1,357 FDA listings and 125 TGA listings. Radiology dominated both markets (FDA 76.5%, TGA 60.8%), but Australia had different specialty diversity to the US, including orthopaedic (2.4%) and dental (3.2%) devices. AI image and signal interpretation was most common (FDA 57.5%, TGA 38.4%), whereas measurement, treatment planning, and workflow support were relatively more prominent in Australia. Nearly all FDA devices were Class II (98.8%), while TGA devices spanned low to high-risk classes. Top contributors to Australia’s AI market were the USA (28.8%), Australia (9.6%), and China (8.8%). Of the 125 TGA listings, 71 (56.8%) had a matching FDA listing. Among these 71 matched TGA listings, 15 were listed in Australia prior to the USA, while the remaining 56 were FDA-listed first. Australia’s AI device market is smaller, but still diverse, and includes multiple Australian-headquartered manufacturers. The substantial overlap between the two lists, predominantly with prior FDA listing, suggests the Australian market draws on internationally developed technologies, although listing dates do not establish when devices became available to clinicians. These descriptive findings provide a benchmark for future comparative and longitudinal research as both markets continue to develop.

Journal of Medical SystemsVol. 50(1)
Griffith University (AU), The University of Queensland (AU), Princess Alexandra Hospital (AU)
Good health and well-being
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon